Insights | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Article | December 02, 2011

Orange Book Listing Opportunities for Drug-Device Combinations

Webinar | October 25, 2011

The Future of Wireless Medical Devices - FCC, FDA, and Patent Considerations

Article | October 21, 2011

Is It Time for FDA to Revise Its Orange Book Rules to Deal with Skinny Labeled Generic Drugs?

Article | December 09, 2010

Skinny Labeling and the Inducement of Patent Infringement

Article | December 04, 2009

New FDA Requirements for Post-Marketing Studies and Clinical Trials Using Patents as a Strategy for Recovering Costs Prior to Generic Entry

Article | May 11, 2009

Generics Behaving Badly: Carve Outs, Off-Label Uses

Article | March 31, 2009

Protecting New Investments in Old Drugs

Blog | January 21, 2009

Drug Labels: The New Orange Book

Article | January 21, 2009

Emerging Weapons Against Generics